mLogica Acquires Innovative Legacy Modernization Firm Reverse Paradigm, Augmenting Their Recent Acquisition of the LIBER Software Suite from Atos
10.8.2021 16:01:00 EEST | Business Wire | Press release
mLogica, a global provider of database, mainframe and application modernization services, today announced it’s releasing the most comprehensive set of tools on the market for mainframe migration to the cloud. It’s a move made possible by their recent acquisition of pioneering Italian mainframe technology firm Reverse Paradigm, as well as several other strategic purchases of key technology players and assets earlier this year.
This follows mLogica’s recent acquisition of the groundbreaking LIBER software suite from French multinational information technology firm Atos. The LIBER tool set lets firms with outdated mainframe applications gain the flexibility, scalability and adaptability only possible in the cloud—while retaining all the stability and functionality of their existing systems.
Longtime experts in database and application modernization to the cloud, with these acquisitions mLogica now offers the most complete migration tool set for both private and public sector organizations that can no longer delay updating their antiquated IT systems. The combined toolset will now be marketed as the LIBER*M Mainframe Modernization Suite.
Says mLogica president and CEO Amit Okhandiar, “One of the most important considerations when approaching a complex project like legacy system modernization is the impact it could have on your business’s day-to-day operations. The more moving parts, the more time-consuming, error-prone and logistically challenging it becomes.”
Okhandiar feels simplifying the modernization process is key for customer success. “With these purchases of Reverse Paradigm and the LIBER suite, mLogica is now the one firm that can provide end-to-end expertise, tools and support for every phase of modernization to the cloud. We streamline the entire process so our clients, and their IT staff, can focus on their daily business—knowing they can trust us to deliver on-time, on-budget and with complete accuracy and security.”
mLogica Senior VP of Solution Architecture and Global Operations, Anthony Veltri concurs, “The most exciting aspect of this purchase is that the tools we’ve acquired can be leveraged when we collaborate on projects with our long-standing partners in mainframe migration and system integration, as well as with global cloud providers.”
“These new acquisitions significantly advance our mission to provide our clients with the most comprehensive set of tools on the market, plus expert service and support, which allows them to dramatically reduce the timeline, risks and cost of modernizing workloads of all sizes.”
Reverse Paradigm’s founder and president, Santino Spagnoli, who will now become mLogica’s VP of Engineering for Mainframe Modernization, feels the move points the way to the future of information technology. “We’re excited to become part of a solution-focused organization, which allows us to provide even greater support to our migration partners—and accelerate innovation for the mainframe modernization market.”
About mLogica
mLogica’s mission is to help drive enterprise efficiency through cloud migration. Founded by professionals from leading technology companies, mLogica specializes in migrating complex, legacy on-premise business applications and databases, both mainframe and distributed, to the cloud.
mLogica leverages its automated distributed systems modernization software suite STAR*M , and their mainframe modernization software, LIBER*M , to migrate legacy systems to the cloud. mLogica also modernizes big data applications with their hyperscale petabyte+ big data software CAP*M , and their software-driven TRAK*M managed services programs.
For more information, visit https://www.mLogica.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005338/en/
Contact information
For mLogica:
Michael Kane
+1 (917) 544 6019
michael.kane@mLogica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom